Circulating MiR-29a, Possible Use as a Biomarker for Monitoring IgA Nephropathy.

作者：Haofei Hu, Qijun Wan, Tong Li, Dongli Qi, Xu Dong, Yi Xu, Hongtao Chen, Hongping Liu, Haogui Huang, Cuimei Wei, Wen-Xiong Zhou, Shilun Jiang, Zihe Mo, Fupeng Liao, Qitao Xu, Yongcheng He · 发表于：PubMed · 年份：2020 · 被引用次数：9 · 研究领域：Chronic Kidney Disease and Diabetes、MicroRNA in disease regulation、Renal Diseases and Glomerulopathies

INTRODUCTION: Previous studies have shown that TGF-β1/Smad3 signaling promotes renal fibrosis by inhibiting miR-29. To date, only few studies have reportedon circulating microRNAs in IgA nephropathy (IgAN). However, the plasma expression of miR-29a and its role in patients with IgAN remains unclear. In this study, we attempted to elucidate whether plasma miR-29a expression can be used as a biomarker for monitoring disease states. METHODS: For this study, 15 healthy subjects, 36 patients with untreated renal biopsy-proven IgAN, and 79 patients with IgAN, who were under treatment for a period of 1 year on an average, all of whom had similar age and gender distributions, were included. The plasma expression of miR-29a in each group was explored by real-time PCR, and the relationship between miR-29a expression and clinical, pathological, and prognostic indicators of IgAN was further evaluated. RESULTS: Relative plasma expression of miR-29a in patients with IgAN was significantly lower than that in healthy controls (P < .001), and these changes in plasma miR-29a could be suppressed by treatment (P < .05). Plasma miR-29a was positively correlated with eGFR and negatively correlated with proteinuria and serum creatinine, irrespective of whether or not the patients with IgAN accepted treatment (P < .05). Plasma miR-29a level was negatively correlated with primary pathological parameters such as crescent formation, Lee's and Oxford classification (P < .05). Kaplan-Meier analysis revea...